iShares Biotechnology ETF (NASDAQ:IBB) Short Interest Down 8.6% in September

iShares Biotechnology ETF (NASDAQ:IBB) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 9,300,000 shares, a decrease of 8.6% from the August 31st total of 10,180,000 shares. Based on an average daily volume of 1,257,200 shares, the days-to-cover ratio is currently 7.4 days.

iShares Biotechnology ETF Trading Up 0.5 %

Shares of NASDAQ:IBB opened at $145.60 on Tuesday. iShares Biotechnology ETF has a one year low of $111.83 and a one year high of $150.57. The business’s fifty day moving average price is $145.69 and its two-hundred day moving average price is $138.91.

iShares Biotechnology ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. acquired a new position in iShares Biotechnology ETF in the 4th quarter valued at $2,771,000. Stifel Financial Corp lifted its position in iShares Biotechnology ETF by 11.7% during the fourth quarter. Stifel Financial Corp now owns 137,897 shares of the financial services provider’s stock worth $18,736,000 after buying an additional 14,457 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in iShares Biotechnology ETF in the 4th quarter worth about $206,000. Holderness Investments Co. purchased a new stake in iShares Biotechnology ETF in the 4th quarter valued at about $863,000. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of iShares Biotechnology ETF by 4.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 33,215 shares of the financial services provider’s stock worth $4,512,000 after acquiring an additional 1,273 shares during the period. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.